10 research outputs found
Development of a simple but effective cancer vaccine consisting of an antigen and a cationic lipid
Human papillomavirus (HPV) oncoproteins E6 and E7 which are constitutively expressed in cervical cancer cells are ideal targets for developing immunotherapies for treatment of existing HPV-associated carcinoma. In this project, we developed a simple, safe, and efficient, peptide-based therapeutic cancer vaccine, DOTAP/E7 complex, which comprises only two molecules: a DOTAP cationic lipid and an MHC class I-restricted peptide antigen derived from HPV-16 E7 protein. TC-1 cell line which is HPV-16 E7+ was used as a tumor model in an H-2b murine system. Tumor-bearing mice showed significant tumor inhibition following a single injection of DOTAP/E7 at the optimal lipid dose, suggesting that DOTAP liposome alone can be a potent adjuvant. E7 peptide formulated with DOTAP was taken up by dendritic cells (DC) and induced DC activation and migration to the draining lymph node (DLN), eliciting antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses. The mechanism of DOTAP as a vaccine adjuvant was revealed by DOTAP-mediated reactive oxygen species (ROS) production in DC. At the optimal lipid dose, DOTAP/E7 generates an adequate level of ROS for the initiation of the vaccine mechanism. In addition, we have improved the vaccine formulation by incorporation of E7-lipopeptide instead of the water-soluble native E7 peptide. The improved DOTAP/E7-lipopeptide vaccine showed a significantly enhanced therapeutic effect, including CTL response and anti-tumor activity. The vaccine was also effective for suppression of tumor growth in later stages of tumor progression, suggesting applications for advanced cancer treatment. Furthermore, we extended the studies of the vaccine efficacy observed in the mouse model to human cells in vitro. Instead of H-2Db-restricted peptide, an HLA-A2-restricted E7 peptide epitope (hE7) was formulated into the liposome. In vitro stimulation of naïve HLA-A2+ human T lymphocytes by DOTAP/hE7-activated autologous DC elicited a stronger clonal T cell proliferation and higher HPV-specific CTL response compared to those stimulated with DC pulsed with hE7 peptide alone. The in vivo CTL and anti-tumor activity induced by DOTAP/hE7 vaccine were demonstrated in an HLA-A2 transgenic mouse model. Overall, our data suggest that DOTAP/hE7 is a potent therapeutic cancer vaccine formulation with potential for clinical applications for the treatment of HPV-related neoplasia
Recommended from our members
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A(mut)) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A(mut)-bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A(mut) arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance
Immune responses of therapeutic lipid nanoparticles
Nanoparticle-based drug delivery is an emerging technology for targeting therapeutics to the diseased site for enhanced therapy and reduced toxicity. A number of pharmaceutical products that involve nanotechnology have been approved for clinical use, and because of altered pharmacokinetics and biodistribution, their profiles of interaction with host cells and resulting toxicity are different from parent agents. This review focuses on the immune responses induced by therapeutic lipid nanoparticles. These immune responses can provoke toxicity, affect pharmacokinetics of the nanoparticles or induce therapeutic effect. This article begins with a general introduction on immune responses and innate and acquired immunity. Specific examples of therapeutic lipid nanoparticles inducing immune responses in each category are presented with detailed discussions on the mechanisms. Current guidelines for evaluating immune response of nanomedicines are summarized. Finally, perspectives and future directions are provided emphasizing mechanistic studies of immune reactions triggered by nanoparticles.</p
Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes
Mefloquine
(Mef), a poorly soluble and highly bitter drug, has
been used for malaria prophylaxis and treatment. The dosage form for
Mef is mostly available as adult tablets, and thus children under
the age of 5 suffer from poor medication adherence. We have developed
a stable, rapidly dissolvable, and palatable pediatric formulation
for Mef using liposomes composed of 1,2-distearoyl-<i>sn</i>-glycero-3-phosphocholine (DSPC) and cholesterol with a mean diameter
of ∼110 nm. Mef was actively loaded into the liposomes via
an ammonium sulfate gradient using the solvent-assisted loading technology
(SALT) developed in our lab. Complete loading of Mef inside the liposomal
core was achieved at a high drug-to-lipid ratio (D/L) of 0.1–0.2
(w/w), and the final drug content in the formulation was ∼8
mg/mL, well above the solubility of Mef (<0.6 mg/mL in simulated
fluids). The strong bitterness of Mef was masked by the liposomal
encapsulation as measured by an electronic tongue. Incubating the
Mef-liposomes (Mef-Lipo) in the simulated gastric fluid (pH 1.2) and
the simulated intestinal fluid containing 3 mM sodium taurocholate
(pH 6.8) induced changes in liposome size and the polydispersity,
resulting in drug release (∼40% in 2 h). However, no drug release
from the Mef-Lipo was measured in the bile salt-free intestinal fluid
or simulated saliva (0% in 3 h). These data suggest that drug release
from the Mef-Lipo was mediated by a low pH and the presence of a surfactant.
Pancreatic lipase did not degrade DSPC in the Mef-Lipo after 8 h of
incubation nor induce Mef release from the liposomes, indicating that
lipid digestion played a minor role for drug release from the Mef-Lipo.
In order to improve long-term room temperature storage, the Mef-Lipo
was lyophilized to obtain a solid formulation, which was completely
dissolvable in water in 10 s and displayed similar in vitro profiles
of release as the liquid form. The lyophilized Mef-Lipo was stable
at room temperature for >3 months. In mice, orally delivered liquid
and lyophilized Mef-Lipo displayed comparable absorption with bioavailability
(BA) of 81–86%, while the absorption of the standard Mef suspension
was significantly lower with BA of 70% and 20% decreased maximal plasma
concentration and area under the curve. Our data suggest that the
Mef-Lipo was a stable, palatable, and bioavailable formulation that
might be suitable for pediatric use
Abstract 224: Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia.
During hematopoiesis, all-trans-retinoic acid (ATRA), a natural derivative of vitamin A, has been shown to induce both myelomonocytic progenitor/stem cell differentiation and self-renewal. Although these opposing effects are likely to be partly due to developmental differences, it has been shown that pro- and anti-differentiation effects of ATRA are mediated by distinct retinoic acid receptor isotypes (RARα and RARγ, respectively). With the exception of acute promyelocytic leukemia (APL), ATRA treatment as a single agent has not been successful in other types of acute myeloid leukemia (AML). We have previously hypothesized that one of the underlying reasons for poor response of non-APL AML to ATRA (pan-RAR agonist) is aberrant expression and/or activities of RAR isotypes favoring RARγ and cell growth versus differentiation. Consistently, we have reported that expression of RARα isoforms, particularly ATRA-inducible RARα2, are down-regulated in AML (Blood. 2008; 111:2374). Epigenetic analysis of patient samples revealed that relative to normal CD33+ cells, the loss of RARα2 in AML is associated with a diminution in levels of histone histone H3 lysine 4 dimethylation (H3K4me2) on the ATRA-responsive RARA2 promoter (a modification associated with transcriptional activation). Interestingly, the H3K4me1/me2 demethylase LSD1/KDM1 (AOF2) is highly expressed in AML patients (www.proteinatlas.org). A number of small molecules that target this enzyme (LSD1i) are in development and, collectively, these data predict that the use of LSD1i will facilitate induction of expression of genes that are required for differentiation of AML cells. In this study we used tranylcypromine (TCP, a monoamine oxidase used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively), which functions a time-dependent, mechanism-based inhibitor of LSD1.
Here we show that TCP unlocked the ATRA-driven therapeutic differentiation response in non-APL AML cell lines including the TEX cell line, which is derived from primitive human cord blood cells immortalized by expression of the TLS-ERG oncogene. TEX cells are >90% CD34+, respond poorly to ATRA and mimic features of primary human AML and leukemia initiating cells (Leukemia. 2005; 19:1794). Consistent with this, ATRA/TCP treatment increased differentiation in primary patient samples. ATRA alone had in general only small effects in primary AML samples and TCP showed minimal activity in most cases. Furthermore, shRNA-mediated knockdown of LSD1 confirmed a critical role for this enzyme in blocking the ATRA response in AML cells.
The effects of ATRA/TCP on AML cell maturation were paralleled by enhanced induction of genes associated with myelomonocytic differentiation, including direct ATRA targets. LSD1i treatment did not lead to an increase in genome-wide H3K4me2, but did increase H3K4 dimethylation of myelomonocytic differentiation-associated genes. Importantly, treatment with ATRA/TCP dramatically diminished the clonogenic capacity of AML cells in vitro and engraftment of cells derived from AML patients in vivo, suggesting that ATRA/TCP may also target leukemic stem cells. These data strongly suggest that LSD1 may, at least in part, contribute to AML pathogenesis by inhibiting the normal function of ATRA in myelomonocytic development and pave the way for effective differentiation therapy of AML
Inhibition of the LSD1/KDM1 histone demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4me2) across the genome, but it did increase H3K4me2 and expression of myeloid-differentiation–associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML